|
Volumn 21, Issue 8, 2011, Pages 2505-2509
|
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors - Implications for early Myasthenia gravis treatment
|
Author keywords
Cholinesterase; In vitro; Inhibitor; Molecular modelling; Myasthenia gravis; Quaternary
|
Indexed keywords
1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE;
ACETYLCHOLINESTERASE;
AMBENONIUM;
CHOLINESTERASE;
CHOLINESTERASE INHIBITOR;
EDROPHONIUM;
ETHOPROP;
QUINOLINE DERIVATIVE;
ARTICLE;
DRUG PROTEIN BINDING;
DRUG SCREENING;
DRUG SELECTIVITY;
DRUG SYNTHESIS;
ENZYME ACTIVE SITE;
IC 50;
IN VITRO STUDY;
KINETICS;
MOLECULAR INTERACTION;
MOLECULAR MODEL;
MYASTHENIA GRAVIS;
ACETYLCHOLINESTERASE;
AMBENONIUM CHLORIDE;
BENZENAMINIUM, 4,4'-(3-OXO-1,5-PENTANEDIYL)BIS(N,N-DIMETHYL-N-2-PROPENYL-), DIBROMIDE;
BINDING SITES;
BUTYRYLCHOLINESTERASE;
CHOLINESTERASE INHIBITORS;
EDROPHONIUM;
HUMANS;
KINETICS;
MOLECULAR DYNAMICS SIMULATION;
MYASTHENIA GRAVIS;
PROTEIN BINDING;
QUINOLINIUM COMPOUNDS;
RECOMBINANT PROTEINS;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 79953288102
PISSN: 0960894X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.bmcl.2011.02.047 Document Type: Article |
Times cited : (28)
|
References (36)
|